Rock Springs Capital Management LP Sage Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $5.57 Million - $14.3 Million	-92,500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $3.89 Million - $7.12 Million	43,500 Added 88.78%	92,500 $14.7 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $608,600 - $769,320	4,000 Added 8.89%	49,000 $7.89 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $759,000 - $2.09 Million	12,500 Added 38.46%	45,000 $7.41 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $2 Million - $2.88 Million	32,500	32,500 $2.03 Million

195

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $430M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.